Weight-loss drug developer BioAge raises $198 million in U.S. IPO
BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the range at $18 per share, the weight-loss drug developer said on Wednesday. The surging popularity of weight-loss drugs,
California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...
BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with ...
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...
Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking ...
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
BioAge Labs (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, visits the Nasdaq ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback